Breast cancer is classified and managed largely on the basisof anatomy — in contrast with lymphoma, which has beenclassified and treated according to grade for more than 20 years.Tumor size and the degree of involvement of the axillary nodesare used to estimate the risk of systemic micrometastases atdiagnosis and, accordingly, whether systemic adjuvant therapy,which improves overall survival in largely unselected populations,is needed.1
A routine question faced by oncologists is, which of the twothirds of patients with hormone-receptor–positive breastcancer require systemic adjuvant chemotherapy to decrease theirchance of recurrence? Although there are . . . [Full Text of this Article]
Source Information
From the Baylor Sammons Cancer Center, Texas Oncology, and US Oncology — all in Dallas.
This article has been cited by other articles:
Badve, S., Turbin, D., Thorat, M. A., Morimiya, A., Nielsen, T. O., Perou, C. M., Dunn, S., Huntsman, D. G., Nakshatri, H.
(2007). FOXA1 Expression in Breast Cancer Correlation with Luminal Subtype A and Survival. Clin. Cancer Res.
13: 4415-4421
[Abstract][Full Text]
Dimitrov, N. V., Colucci, P., Nagpal, S.
(2007). Some Aspects of the Endocrine Profile and Management of Hormone-Dependent Male Breast Cancer. The Oncologist
12: 798-807
[Abstract][Full Text]
Done, S. B.
(2006). Diagnostic Array Comparative Genomic Hybridization: Is It Ready for Prime Time?. J. Mol. Diagn.
8: 527-527
[Full Text]
Previous
